MDS Current Trials UK

We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust 

  1. SUB-TYPE OF MDS:Patients with primary or secondary AML acute myeloid leukaemia (including disease
    transformed from Myelodysplastic Syndrome) who fail to enter complete morphological remission or have persistence of cytogenetic abnormality following intensive combination chemotherapy at day+100 post-transplant
  2. SEVERITY OF MDS: AML
  3. NAME OF DRUG: Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) that express
    B7.1 (CD80) and IL-2 (AML cell vaccine)
  4. Aims and benefits: This is a phase 1 study aimed at determining the safety of the AML cell vaccine.
  1. Basic inclusion criteria:
    • ≥ 18 years of age
    • Prior treatment with Myeloablative or Reduced Intensity Conditioned allogeneic HSCT
    • Morphological relapse of disease as defined by the presence of >5% bone marrow blasts post allogeneic HSCT
    • Presence of ≥25% donor CD3 chimerism at time of disease relapse
    • Patients need to have achieved morphological remission (as defined by <5% blast in the bone marrow) following cytoreductive chemotherapy, for treatment of disease relapse.
    • HIV negative at relapse.
    • Absence of active viral infections including HTLV-1, hepatitis B or C.
    • Adequate renal and liver function
    • ECOG performance status of 0, 1 or 2
  2. Basic exclusion criteria:
    • Life expectancy of <24 weeks
    • Patients not fit for cytoreductive chemotherapy following relapse
    • Evidence of graft versus host disease
    • Concurrent use of other forms of anti-leukaemic therapy for relapse
    • Other malignancy with the exception of carcinoma in situ.
    • Significant history of heart disease (unstable angina, myocardial infarction within the past six months)
    • Positive pregnancy test
  3. Trial sites/locations and name of physician in charge of trial (none are currently recruiting):
    • Kings College Hospital

Please read information and always discuss trial information with your own physician.

Paper of the Month

Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure

Visit our archives

IPSS-R MDS Risk Assessment Calculator

Revised International Prognostic Scoring System (IPSS-R) for Myelodysplastic Syndromes Risk Assessment Calculator

calculator

Click here

MDS Fact Sheet

MDS Factsheet for GPs General Practicioners

MDS Fact Sheet

Click here

Varicella Vaccine in MDS

Urgent Clarification on varicella vaccine policy

Current advice from the UK MDS Forum is not to give the Live Varicella Vaccine to patients with MDS.

Please read below correspondence between Professor Salisbury and Dr George Follows, the latter on behalf of the CLL Forum, on the varicella vaccine policy.
This is an external link to the British Society for Haematology  Click here

NICE Guideline

Lenalidomide for treating myelodysplastic syndromes (MDS) associated with an isolated deletion 5q cytogenetic abnormality.

NICE logo

Click here

BSH Guidelines

This is an external link to the home of the British Society for Haematology (BSH). 

BSH Logo Strapline RGB

Click here